Patents by Inventor Ibon Gutierro Aduriz
Ibon Gutierro Aduriz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10335366Abstract: The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.Type: GrantFiled: November 26, 2014Date of Patent: July 2, 2019Assignee: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Ibon Gutierro Aduriz, Guillermo Franco Rodríguez
-
Publication number: 20190151230Abstract: Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: ApplicationFiled: January 22, 2019Publication date: May 23, 2019Applicant: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Publication number: 20190154601Abstract: The present invention describes an analytical method by nuclear magnetic resonance of glycosaminoglycans in general, and of heparins and low molecular weight heparins and their derivatives in particular, which allows their identification and the relative quantification of its characteristic signals by 1H-NMR and/or 1H-13C HSQC.Type: ApplicationFiled: January 18, 2019Publication date: May 23, 2019Applicant: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Guillermo FRANCO RODRIGUEZ, Ibon GUTIERRO ADURIZ
-
Patent number: 10285936Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.Type: GrantFiled: January 30, 2015Date of Patent: May 14, 2019Assignee: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Guillermo Franco Rodríguez, Ibon Gutierro Aduriz
-
Publication number: 20190117554Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.Type: ApplicationFiled: December 14, 2018Publication date: April 25, 2019Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Patent number: 10195138Abstract: Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: GrantFiled: July 11, 2018Date of Patent: February 5, 2019Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Patent number: 10182982Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.Type: GrantFiled: April 4, 2018Date of Patent: January 22, 2019Assignee: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Publication number: 20180318208Abstract: Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: ApplicationFiled: July 11, 2018Publication date: November 8, 2018Applicant: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Patent number: 10085936Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.Type: GrantFiled: November 30, 2012Date of Patent: October 2, 2018Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Patent number: 10058504Abstract: Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.Type: GrantFiled: November 30, 2012Date of Patent: August 28, 2018Assignee: LABORATORIOS FARMACEUTICOS ROVI, S.A.Inventors: Ibon Gutierro Aduriz, Maria Teresa Gomez Ochoa
-
Publication number: 20180221272Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.Type: ApplicationFiled: April 4, 2018Publication date: August 9, 2018Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Ibon GUTIERRO ADURIZ, Maria Teresa GOMEZ OCHOA
-
Publication number: 20150196485Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.Type: ApplicationFiled: January 30, 2015Publication date: July 16, 2015Applicant: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Guillermo FRANCO RODRIGUEZ, Ibon Gutierro Aduriz
-
Publication number: 20150150791Abstract: The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.Type: ApplicationFiled: November 26, 2014Publication date: June 4, 2015Applicant: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Ibon GUTIERRO ADURIZ, Guillermo FRANCO RODRÍGUEZ
-
Publication number: 20150147398Abstract: An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.Type: ApplicationFiled: November 26, 2014Publication date: May 28, 2015Applicant: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Ibon GUTIERRO ADURIZ, Guillermo FRANCO RODRÍGUEZ
-
Patent number: 8802156Abstract: A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 ?mol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition possesses a moisture content of 10% wt or less. A pharmaceutical dosage form containing the pharmaceutical composition, and their use for the treatment of diseases or disorders therapeutically responsive to the glycosaminoglycan.Type: GrantFiled: July 29, 2011Date of Patent: August 12, 2014Assignee: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Guillermo Franco Rodriguez, Ibon Gutierro Aduriz
-
Patent number: 8361509Abstract: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.Type: GrantFiled: January 23, 2012Date of Patent: January 29, 2013Assignee: Laboratorios Farmacéticos Rovi, S.A.Inventors: Iván López-Belmonte Encina, Ibon Gutierro Aduriz, Philippe Maincent
-
Patent number: 8257744Abstract: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.Type: GrantFiled: May 13, 2010Date of Patent: September 4, 2012Assignee: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Ivan Lopez-Belmonte Encina, Ibon Gutierro Aduriz, Philippe Maincent
-
Publication number: 20120189698Abstract: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.Type: ApplicationFiled: January 23, 2012Publication date: July 26, 2012Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Iván LÓPEZ-BELMONTE ENCINA, Ibon GUTIERRO ADURIZ, Philippe MAINCENT
-
Publication number: 20120022020Abstract: A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 ?mol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition possesses a moisture content of 10% wt or less. A pharmaceutical dosage form containing the pharmaceutical composition, and their use for the treatment of diseases or disorders therapeutically responsive to the glycosaminoglycan.Type: ApplicationFiled: July 29, 2011Publication date: January 26, 2012Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Guillermo FRANCO RODRÍGUEZ, Ibon GUTIERRO ADURIZ
-
Publication number: 20100316722Abstract: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.Type: ApplicationFiled: May 13, 2010Publication date: December 16, 2010Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Iván LOPEZ-BELMONTE ENCINA, Ibon GUTIERRO ADURIZ, Philippe MAINCENT